Application of Amide Proton Transfer-Weighted Imaging in Predicting Pathological Complete Response After Neoadjuvant Therapy of Rectal Cancer
A Multi-center Study on Amide Proton Transfer-Weighted Imaging in Predicting Pathological Complete Response After Neoadjuvant Therapy of Rectal Cancer
Sixth Affiliated Hospital, Sun Yat-sen University
320 participants
Oct 22, 2024
OBSERVATIONAL
Conditions
Summary
The goal of this observational study is to learn about the amide proton transfer-weighted imaging for rectal cancer response assessment after neoadjuvant therapy. The main question it aims to answer is: • Does amide proton transfer-weighted imaging predict the cancer response before surgery? Participants will underwent amide proton transfer-weighted imaging as part of their regular MRI examination.
Eligibility
Inclusion Criteria4
- Locally advanced rectal cancer(cT3-4, or cN+), resectable, histologically confirmed rectal adenocarcinoma
- Received neoadjuvant therapy before surgery
- Complete radical resection of rectal cancer and postoperative pathological examination
- Informed consent and signed the informed consent form
Exclusion Criteria7
- Poor image quality, such as severe artifacts
- Complicated with intestinal obstruction, intestinal perforation and other cases requiring surgical treatment
- The interval between preoperative MRI and surgery was more than 2 weeks
- Prior treatment for rectal cancer
- History of other malignant tumors
- Patients who cannot undergo MRI examination due to contraindications or relative contraindications
- Patients were lost to follow-up or voluntarily withdrew from the study due to adverse reactions or other reasons
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06719414